Læknablaðið - 15.11.2005, Page 20

EDstofal08
NÝTT LYF VIÐ PARKINSONSSJÚKDÓMI
Azilect® 1 mg- marktæk verkun í einlyfjameðferð1
Azilect® 1 mg - marktæk verkun gefið með
levódópa2
Azilect® 1 mg - einu sinni á dag, engin títrun
og þolist vel3
Azilect® rasagílín
Einu sinni á dag
rasagílín
Einfaldlega áhrifaríkt
Sérlyfjatexti á bls. 891
Heimildir
1. Parkinson Study Croup. A Controlled Trial of Rasagiline in Early Parkinson Disease.TheTEMPO Study.Arch Neurol 2002; 59:1937-43
2. Rascol et al, for the LARCO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disea§e and motor þuctuations (LARGO, Lasting effect in Adjunct therapy with
Rasagiline Civen Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365:947-54
3. Parkinson Study Group.A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated PatientsWith Parkinson Disease and Motor Fluctuations.The PRESTO Study.Arch Neurol
2005; 62:241-248